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Background: There is a need for new small molecule pre-mRNA splicing inhibitors as biotools.
Results:High throughput screening resulted in the identification of smallmolecule splicing inhibitors that are active in vitro and
in cells.
Conclusion: New small molecules for studying pre-mRNA splicing in vitro and in cells are identified.
Significance: Small drug-like molecules are identified that modulate splicing in vitro and in cells.
Eukaryotic pre-mRNA splicing is an essential step in gene
expression for all genes that contain introns. In contrast to tran-
scription and translation, few well characterized chemical
inhibitors are available with which to dissect the splicing pro-
cess, particularly in cells. Therefore, the identification of spe-
cific small molecules that either inhibit or modify pre-mRNA
splicing would be valuable for research and potentially also for
therapeutic applications. We have screened a highly curated
library of 71,504 drug-like small molecules using a high
throughput in vitro splicing assay. This identified 10 new com-
pounds that both inhibit pre-mRNA splicing in vitro andmodify
splicing of endogenous pre-mRNA in cells. One of these splicing
modulators, DDD00107587 (termed “madrasin,” i.e. 2-((7me-
thoxy-4-methylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-
4(3H)-one RNAsplicing inhibitor), was studied in more detail.
Madrasin interferes with the early stages of spliceosome assembly
and stalls spliceosome assembly at the A complex. Madrasin is
cytotoxic at higher concentrations, although at lower concentra-
tions it induces cell cycle arrest, promotes a specific reorganization
of subnuclear protein localization, andmodulates splicing of mul-
tiple pre-mRNAs in bothHeLa andHEK293 cells.
The removal of introns from pre-mRNA is an essential step
in gene expression in eukaryotes. Deep sequencing data have
shown that 95% of all human genes are spliced, often in a
developmental, tissue-specific, and/or signal transduction-de-
pendent manner (1). Pre-mRNA splicing is mediated by the
spliceosome, a large RNA-protein complex that in humans
consists of five snRNAs (U1,U2,U4,U5, andU6) andnumerous
proteins (2). The spliceosome coordinates the two separate
transesterification reactions required for intron removal and
the completion of the splicing cycle. The splicing of pre-mRNA
takes place in the cell nucleus and involves the stepwise assem-
bly of a separate spliceosome complex on each intron in a
pre-mRNA transcript. In most, if not all cases, spliceosomes
assemble on nascent transcripts while transcription of the gene
is still in progress.
The maintenance of high fidelity pre-mRNA splicing is
important to allow accurate protein expression. Point muta-
tions affecting pre-mRNA sequences involved in splice site rec-
ognition and splicing are thought to be responsible for15% of
all inherited human diseases (3, 4). Aswell as its essential role in
removing introns to permit protein expression, different pat-
terns of alternative splicing allow the creation of multiple
mRNAs encoding different proteins from a single gene. Alter-
native splicing is also often disrupted in many forms of disease,
including cancer. For example, this can be due to either altered
expression ormis-localization of RNA-binding proteins, result-
ing in changes in the pattern of alternatively spliced mRNAs
(5, 6).
Smallmolecules can be powerful tools for dissecting complex
biological processes, as is well documented for transcription
and translation. This is typified by the antibiotics used to study
translation in prokaryotes, e.g. puromycin and viomycin, which
inhibit the prokaryotic ribosome (7). In contrast, there are
no comparable classes of natural antibiotics that inhibit the
pre-mRNA splicing process. This is likely because natural anti-
biotics are mostly produced by fungi to kill bacteria, which lack
introns in protein-coding genes and thus do not require splic-
ing for protein expression. In recent years, however, several
natural compounds, and their synthetic derivatives, have been
reported to inhibit splicing, either in vitro, or in cells, or both.
These include FR901464, spliceostatinA (SSA)2 (8), E7107, pla-
dienolide B, pladienolide D (9), GEX1A (10), sudemycin (11),
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and isoginkgetin (12). With the exception of isoginkgetin,
whose target is currently unknown, all the other compounds
target the SF3b subunit of the U2 snRNP (13).
Several high throughput screening approaches have also been
undertaken to identify smallmolecules that act as specific splicing
inhibitors, albeit with limited success. Most of the molecules that
have been identified in these assays either modify splicing in cells
but arenot showntodoso in vitro, e.g.clotrimazol, flunarizine, and
chlorhexidine (14), or else they inhibit splicing invitrobuthavenot
beenshowntomodulate splicingalso incells,e.g.naphthoquinone,
tetrocarcin, and ANSC659999 (15).
Two main types of high throughput assay have been estab-
lished for the identification of new pre-mRNA splicing modifi-
ers as follows: (a) cell-based splicing assays, using reporter con-
structs as a readout (12, 16) and (b) high throughput in vitro
splicing assays, using either ELISA or quantitative PCR tech-
niques for signal detection (15, 17, 18).
The high throughput in vitro splicing assay developed by
Samatov et al. (17) allows the identification of small molecule
splicing inhibitors that affect either spliceosome assembly, acti-
vation, and/or step 1 catalysis. This is achieved by using the
PM5pre-mRNA,which lacks both the 3-splice site and 3 exon
of a typical pre-mRNA and therefore stops the splicing reaction
after C complex formation. Addition of the PM5 pre-mRNA to
a splicing reaction containing FLAG-tagged DDX41, a compo-
nent of the spliceosomal C complex, allows detection of the C
complex using an anti-FLAG antibody. The high throughput
screening in vitro splicing assay established by Samatov et al.
(17) thus allows the detection of small molecules that interfere
with the splicing process at any stage up to C complex forma-
tion. We therefore used this assay to screen a highly selected
library of 71,504 smallmolecules developed by theUniversity of
DundeeDrugDiscoveryUnit to identify new splicing inhibitors
(19).
Here, we describe the discovery of 13 new small chemical
compounds that inhibit splicing in vitro. 10 out of these 13
compounds also inhibit splicing in cultured human cell lines. By
way of example, we characterize the effect of one of these com-
pounds, DDD00107587 (madrasin), both on splicing in vitro
and in cells.
EXPERIMENTAL PROCEDURES
High Throughput Screening—The high throughput screen
was performed using an adapted version of the high throughput
in vitro splicing assay published by Samatov et al. (17) and the
in-house small molecule compound library of the DrugDiscov-
ery Unit, University of Dundee. In short, using aWellmate bulk
reagent dispenser (Thermo Fisher, Waltham, MA), 384-well
polystyrene high protein-binding microplates (Greiner) were
coated with rabbit polyclonal antibodies to maltose-binding
protein (Abcam, Cambridge, UK) before PM5 pre-mRNA
bound by MS2-MBP was added to the microplates and incu-
bated for 1 h. 0.1 l of test compounds were added to the
pre-mRNA-labeled microplates by using a Hummingbird
(Digilab Genomic Solutions Ltd., Marlborough, MA) to pro-
duce a final concentration of 50M. The splicing reactions con-
taining HEK293 whole cell extract from cells stably expressing
FLAG-taggedDDX41 protein and themonoclonal anti-FLAG
M2-peroxidase (Sigma) were prepared at room temperature,
and 20 l/well were added to the plates using the Biomek FX
automated workstation (Beckman Coulter, High Wycombe,
UK). The plates were incubated at 26 °C for 90 min before they
were washed four times with wash buffer. 20 M SuperSignal
ELISA Femto Maximum Sensitivity Substrate (Pierce, Thermo
Fisher, Rockford, IL)was then added, and the luminescencewas
monitored after 5min of incubation at room temperature using
the TopCount microplate luminometer (PerkinElmer Life
Sciences).
Data Analysis—For all primary and potency screen data
points, the relative luminescence units per well weremeasured.
From cross-talk-corrected data, a percentage inhibition value for
each test compound was determined as follows: % inhibition 
100 ((RLUTEST  RLULOW)/(RLUHIGH  RLULOW))  100.
RLUHIGHmedian of all “high” signal (“uninhibited” control)
wells per plate. RLULOW  median of all “low” signal
(noMS2-MBP-pre-mRNA) wells per plate. Robust Z was cal-
culated for each plate based on the median and scaled median
absolute deviation (1.4826  median absolute deviation) for
RLUHIGH and RLULOW from all wells per plate. All data pro-
cessing was conducted within the activity base using normal-
ized data as defined above. Database querying and report cre-
ation was undertaken using SARgen version 7.3.0.2 and
SARview version 7.1.1 from IDBS (London, UK). All IC50
curve fitting was undertaken within the ActivityBase XE uti-
lizing the underlying “Math IQ” engine of XLfit version
5.1.0.0 from IDBS. A four-parameter logistic dose-response
curve of the following form was utilized for compound
potency determination as shown in Equation 1,
y 
a  d
1   x/c	b
 d (Eq. 1)
where a is the minimum; b is the Hill slope; c is the EC50 value;
and d is the maximum. Data are presented as the mean pEC50
with the standard error of the mean of n experiments.
Cell Culture, RNA Isolation, and RT-PCR—HeLa and HEK293
cells were purchased from ATCC and cultured in Dulbecco’s
modified Eagle’s medium supplemented with 10% fetal
bovine serum, 2 mM glutamine (Invitrogen), and 100 g/ml
streptomycin (100 stock, Invitrogen). Total RNA was
extracted from cells using the NucleoSpin RNA II kit (Mach-
erey-Nagel, Du¨ren, Germany) according to the manufacturer’s
instructions. 200 ng of total RNA was reverse-transcribed and
amplified using the One-step RT-PCR kit (Qiagen, Venlo,
Netherlands) according to the manufacturer’s instructions.
Primer sequences are as follows: HPV18 E6, forward 5-GCG-
ACCCTACAAGCTACCTA-3 and reverse 5-GCACTGGC-
CTCTATAGTGCC-3 (20); E1A, forward 5-CCGAAGAAA-
TGGCCGCCAGTC-3 and reverse 5-GGACGCCGGGTAG-
GTCTTGC-3 (21); RIOK3, forward 5-GCTGAAGGACCAT-
TTATTACTGGAG-3 and reverse 5-TTCTTGCTGTGTTC-
TTTCTCCCACA-3; Hsp40, 5-GAACCAAAATCACTTTC-
CCCAAGGAAGG-3 and reverse 5-AATGAGGTCCCCAC-
GTTTCTCGGGTGT-3 (22); BRD2, 5-CAAAATTATAAA-
ACAGCCTATGGACATG-3 and reverse 5-TTTTCCAGC-
GTTTGTGCCATTAGGA-3 (22);MCL1, forward 5-GAGG-
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AGGAGGAGGACGAGTT-3 and reverse 5-ACCAGCTCC-
TACTCCAGCAA;CCNA2, forward 5-TCCTCGTGACTGG-
TTAGTT-3 and reverse CCCGTGACTGTGTAGAGTGC-
3; AURKA, forward 5-CTTGGATCAGCTGGAGAGCTT-3
and reverse 5-AGCTGATTCTTTGTTTTGGCAAT-3; p27
forward 5-CAGCTTGCCCGAGTTCTACT-3 and reverse
5-GTCCATTCCATGAAGTCAGCG-3.
In Vitro Transcription and Nonradioactive in Vitro Splicing
Reaction—The adenovirus pre-mRNA Ad1 was transcribed in
vitro using the RNAMaxx High Yield Transcription kit (Agi-
lent, Santa Clara, CA) according to the manufacturer’s instruc-
tion, followed by a DNase I digestion and RNA clean up using
the RNeasy kit (Qiagen).
Standard splicing reactions were carried out in 30% HeLa
nuclear extract (Computer Cell Culture Centre, Seneffe, Bel-
gium) in the presence of either DMSO or compound and incu-
bated at 30 °C for 90min. The splicing reaction was followed by
a heat inactivation step of 5 min at 95 °C before the samples
were subjected to proteinase K (Qiagen) digestion for 30min at
55 °C and another heat inactivation step at 95 °C for 5min. The
spliced and nonspliced RNA was amplified by using the one-
step RT-PCR kit (Qiagen) according to the manufacturer’s
instructions. PCR products were separated by electrophoresis
using 1% agarose gels containing SYBR safe DNA gel stain
(Invitrogen).
Radioactive in Vitro Splicing Reaction andNative Gels—Radio-
active in vitro splicing reactions were performed as described pre-
viously (1) using either 32P-labeled pBSAd1 pre-mRNA substrate
or 32P-labeled MINX pre-mRNA substrate (23). Splicing com-
plexeswereanalyzedona lowmeltingpointagarosegel (1.5%,w/v)
as described previously (24) and visualized by phosphorimaging
(Typhoon 8600, GEHealthcare).
Cell Fixation and Immunofluorescence Analysis—HeLa cells,
treated either with DMSO or compound, were grown on cov-
erslips in DMEM for 24 h at 37 °C before fixing with 4% para-
formaldehyde in PHEMbuffer for 10min at room temperature.
After rinsing the cells with PBS, the cells were permeabilized
with 0.5% Triton X-100 in PBS prior to incubation with the
primary antibodies, i.e. anti-SC35 (Abcam, Cambridge, UK),
anti-coilin (ProteinTech, Chicago, IL), anti-Y12 (Dundee Cell
Products, Dundee, UK), anti-TMG (Calbiochem), and anti-
SMN (BDBiosciences). After incubation with the primary anti-
body for 1 h at room temperature, the coverslips were washed
twice with 0.5% of Tween 20 in PBS for 5 min before they were
incubated with the dye-conjugated secondary antibody for 30
min. Cells were then stained with DAPI (Sigma), and the cov-
erslips were mounted in Vectashield medium (Vector Labora-
tories, Peterborough, UK). The samples were visualized using
a fluorescence microscope (Zeiss, Jena, Germany; Axiovert-
DeltaVision Image Restoration; and Applied Precision, LLC).
Flow Cytometry Analysis—HeLa cells were seeded in 6-well
plates, and after 24 h cells were treated with compound. The
cells were harvested after 4, 8, and 24 h and then washed twice
with PBS, resuspended in ice-cold 70% ethanol, and fixed at
room temperature for 30 min. Fixed cells were then washed
twice with PBS, and resuspended in propidium iodide solution
(50 g/ml propidium iodide and 100 g/ml ribonuclease A in
PBS). Cells were incubated in propidium iodide solution for 30
min and then analyzed by flow cytometry on a FACSCalibur
(BD Biosciences). The flow cytometry data were analyzed using
FlowJo (Treestar Inc., Ashland, OR).
Pulse Labeling of HeLa Cells with EdU and EU—Newly syn-
thesizedDNAorRNAwas detected by using either theClick-iT
EdU imaging kit (Invitrogen) or the Click-iT RNA imaging kit
(Invitrogen). In brief, HeLa cells were grown for 24 h in the
presence of either DMSO or compound and pulse-labeled
using either EdU or EU for 20 min. The cells were then fixed,
and the Click-iT detection was performed according to the
manufacturer’s manual.
RESULTS
High Throughput Screening—To identify small molecules
that inhibit the human spliceosome, we performed a high
throughput in vitro screen using a splicing assay (17), optimized
for robotic screening as outlined in Fig. 1. Thus, the PM5
pre-mRNA was immobilized on anti-MBP antibody-coated
384-well microplates via the MS2-MBP fusion protein. This
was incubated in a splicing reaction containing HEK293 whole
cell splicing extract, including a FLAG-tagged version of the
DEAD box ATPase DDX41. As the PM5 pre-mRNA lacked the
3 exon and the 3-splice site, the second step of the splicing
reaction could not be performed, and as a consequence, the
splicing reaction was stalled after C complex formation. The
presence or absence of the C complex on the PM5 pre-mRNA
was detected using a horseradish peroxidase-labeled anti-
FLAG antibody, and the luminescence was monitored using
the TopCount microplate luminometer (PerkinElmer Life
Sciences).
A single point screenwas performedwith a selected library of
71,504 small molecules, each at a final concentration of 50 M.
FIGURE 1. Schematic representation of in vitro splicing high throughput screening. 384-well plates coatedwith anti-MBP antibodieswere incubatedwith
amix of pre-mRNA andMS2-MBP fusion protein for 1 h. After addition of 50M compound, the splicing reaction containing anti-FLAG antibodies was added,
and the splicing reaction was incubated for 90 min at 26 °C. The addition of chemiluminescent substrate for 5 min is followed by signal detection with the
TopCount microplate luminometer.
Identification of New Small Molecule Splicing Inhibitors
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The test library used a combination of a diverse set (63,874
compounds) and several target-type focused sets, i.e. nuclear
hormone receptor (2,407), epigenetic modifier (2,664), and
kinase (2,559). We chose to follow 352 compounds from the
primary screen. This resulted in all molecules giving 52%
splicing inhibition being investigated further (Tables 1 and 2).
To reduce false-positive results e.g. caused by compounds
that restrict the accessibility of the DDX41 antibody to its tar-
get, the 352 hit compounds were rescreened using a separate in
vitro splicing assay format with a nonradioactive RT-PCR-
based in vitro splicing reaction (Fig. 2). For the secondary
screen, a different pre-mRNA, i.e. the adenovirus-related Ad1
transcript made from plasmid pBSAd1 (25), was used as a tem-
plate pre-mRNA, and separate assays were carried out in the
presence of (a) HeLa nuclear extract and (b) HEK293 total cell
lysate. A final concentration of 500 M compound was chosen
for this screen tomaximize detection of active compounds. The
splicing reactions, which were carried out for 90 min, were fol-
lowed by a proteinaseK digestion and a RT-PCR tomeasure the
ratio of spliced/unspliced RNA (see “Experimental Proce-
dures”). This secondary screen reduced the original number of
352 potential hits to 29 molecules that consistently showed
inhibition of splicing in each assay format (supplemental Table
S1).
DMSO stocks of all 29 compounds were tested by liquid
chromatography-mass spectrometry (LC-MS) to confirm the
identity, and the composition of each was as expected. 20 of the
29 compounds passed the quality assurance test (supplemental
Table S1). For six compounds, the LC-MS test identified a large
percentage of impurities, and another three compounds failed
due to incorrect molecular weight. The 20 remaining hit com-
pounds were grouped by chemical similarity into six chemical
series. Compoundswere triaged to removemolecules predicted
to be either chemically reactive or unstable. In addition, mole-
cules that have demonstrated frequent activity across a broad
range of assays, possibly as a result of being fluorescent, redox
active, or aggregating, were removed. One series stood out,
however, with three of the most active hit compounds all
belonging to a series of aminoquinazolines. These compounds
have no obvious undesirable structural features with respect to
potential chemical development and have promising physical
properties, as represented byDDD00107597,which has aClogP
of 3.3 and aMr of 281.
Validation of Hit Compounds—Next, we sourced 33 ana-
logues of DDD00107597, both from commercial sources and
through in-house synthesis of new compounds. The 33 ana-
logues and DDD00107597 were designed to investigate which
structural features are required for splicingmodulation. A third
round of in vitro screening was then performed to confirm the
ability of these related compounds to inhibit pre-mRNA splic-
ing. This time the compounds were all tested in two different in
vitro splicing assays as follows: (a) an in vitro splicing assay,
incubated with HeLa nuclear extract and the radiolabeled ade-
novirus-derived MINX pre-mRNA (26), and (b) a nonradioac-
tive RT-PCR based in vitro splicing assay with the Ad1
pre-mRNA, as described above for the secondary screen.Out of
this group of 34 compounds, 13 inhibited splicing in at least one
assay, with four of these compounds consistently inhibiting
pre-mRNA splicing in both assay systems. Of the nine com-
pounds that showed assay-specific splicing inhibition, seven
inhibited splicing only in the nonradioactive PCR-based in vitro
splicing assay using the Ad1 pre-mRNA, and two compounds
only inhibited splicing of the MINX pre-mRNA (supplemental
Table S2). The reason for these assay-specific inhibitory effects
was not clear, and these compounds were not investigated fur-
ther. We focused instead on the compounds that consistently
inhibited splicing in both in vitro assay formats.
DDD00107587 Inhibits Splicing in Vitro—Compound
DDD00107587 (Fig. 3A), one of the four compounds that inhib-
ited splicing of both the MINX and the Ad1 pre-mRNAs
(supplemental Table S2), was studied in more detail (Fig. 3). In
vitro splicing reactions with either radiolabeled MINX or Ad1,
pre-mRNAs, were carried out for 2 h in the presence of increas-
ingDDD00107587 concentrations (Fig. 3B). Splicing of theAd1
pre-mRNAwas completely inhibited at a final concentration of
62.5 M, whereas splicing of the MINX pre-mRNA was com-
pletely inhibited at 150 M.
DDD00107587 Stalls Spliceosome Assembly at the A Com-
plex Formation—The spliceosome assembles onto pre-mRNA
in a stepwise pathway that involves the formation of assembly
intermediate sub-complexes. Native agarose gels were used to
separate spliceosomes and assemble intermediate complexes to
investigate the effect ofDDD00107587 on the assembly of splic-
ing complexes on the MINX pre-mRNA. When the splicing
assays were carried out in the presence of a DMSO negative
control, the native gel shows separation of the H, A, and B
complexes. At early times after the start of the splicing reaction
(2 and 7 min), mainly A and B complexes are visible. In the
presence of 250MDDD00107587, which blocks the formation
of spliced mRNA, the kinetics of spliceosome assembly differ
dramatically. After 2min, H complexes and small amounts of A
complex can be observed. At later times, A complexes accumu-
late; however, no progression to either the B complex ormature
spliceosome was detected (Fig. 3C).
These data suggest that DDD00107587 inhibits the forma-
tion of spliceosome complexes subsequent to complex A for-
mation. A block of assembly after A complex formation has also
been reported for isoginkgetin (12) and spliceostatin A (27). In
the case of SSA, however, it was shown that the A complex that
forms lacks critical RNA-protein interactions and is therefore
relatively instable (28).
TABLE 1
Summary of screen statistics (average S.D.)
Criterion Result
Valid plates/total plates 217/252
Signal/background 10 62
 37
Robust high control CV (%) 15 7.2
 2.5
Robust Z 0.5 0.75
 0.08
TABLE 2
Summary of screen outcome
Output Result % total
No. of compounds screened 71,504
Hit identification threshold 52%
Putative hits52% 352 0.49
Putative hits75% 112 0.16
Putative hits90% 54 0.07
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DDD00107587 Alters Pre-mRNA Splicing in Vivo—Next, we
investigated the effect of DDD00107587 on the splicing of
endogenous pre-mRNAs in vivo. HeLa and HEK293 cells
were each treated with either DMSO, as a negative control,
or with DDD00107587 at a final concentration of 10, 20, or
30 M, for either 4, 8, or 24 h. After incubation, the cells were
harvested, and total RNA was extracted. 200 ng of total RNA
was used in RT-PCR assays to detect both intron inclusion in
transcripts from the RIOK3, BRD2, and Hsp40 genes and
changes in the alternative splicing of the MCL1, CCNA2,
FIGURE 2. Secondary screen.A, schematic representation of the RT-PCR in vitro splicing assay. 20-l splicing reactionwas incubated in the presence of 500M
compound at 30 °C for 90 min before the splicing reaction was stop by heat inactivation. After proteinase K digestion, the spliced and unspliced RNA is
amplified by RT-PCR. B shows examples of compounds that either inhibit pre-mRNA splicing or do not interfere with the splicing reaction. The star indicates
splicing reactions that were inhibited. Lane M, marker (hyperladder, 1 kb).
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AURKA, and p27 pre-mRNAs. In addition, primers were
chosen to detect the splicing of the HPV18 E6 (human pap-
illomavirus type 18) RNA in HeLa cells and the adenovirus
E1A RNA in HEK293 cells.
Fig. 4A shows the effect on pre-mRNA splicing changes
induced by DDD00107587 in HeLa cells. Although no splicing
inhibition of the Hsp40 pre-mRNA could be detected at the
concentrations and time points tested, inhibition of splicing of
each of the RIOK3, HPV18, and BRD2 pre-mRNAs was
observed after 4 h of treatment at 30 M. Only a slight increase
in inhibition of pre-mRNA splicing over timewas seen formost
HPV18 E6 and BRD2 pre-mRNAs. DDD00107587 potently
inhibited splicing of theRIOK3 pre-mRNA,with95% splicing
inhibition at 30 M for 24 h and80% splicing inhibition at 20
M for 24 h.
Exon skipping after DDD00107587 treatment was observed
for all four genes (MCL1, CCNA2, AURKA, and p27) examined.
The strongest effect was observed on exon 2 skipping of the
MCL1 pre-mRNA. 4 h after addition of DDD00107587 to
HeLa cells, a significant shift from the long splice variant of
MCL1 (MCL1L) to the short splice variant (MCL1S) was
observed at concentrations of 20 and 30 M. Over time this
shift increased until almost exclusively the short isoform was
expressed at these concentrations. At 10 M, low levels of
MCL1S were detected, which did not increase over time.
Weak exon skipping was observed for AURKA and p27 after
4 h at concentrations of 20 and 30 M DDD00107587.
Changes in alternative splicing of AURKA and p27 increased
slightly over time. DDD00107587 treatment resulted only in
low amounts of alternatively spliced CCNA2 transcripts
after 24 h at 30 M.
The results forHEK293 cells are very similar to those inHeLa
cells (Fig. 4B), with little or no pre-mRNA splicing inhibition
detected in the case of the Hsp40 pre-mRNA, but clear inhibi-
tion of splicing of the RIOK3 and BRD2 pre-mRNAs was
detected 24 h after treatment at a final concentration of 30 M.
The alternative splicing of theE1A genewas also changed in the
presence of DDD00107587 in a dose-dependent manner.
Whereas treatment of HEK293 cells with 10MDDD00107587
led to a shift toward formation of the 9 S splice variant, 20 and
30 M DDD00107587 resulted in the accumulation of 13 S
splice products. In HEK293 cells, exon skipping for the four
transcripts testedwas only detected for the twohighest concen-
trations of DDD00107587, 20 and 30 M. As in HeLa cells,
DDD00107587 had the greatest effect on the alternative splic-
ing of MCL1 with significantly more MCL1S expressed than
MCL1L after 24 h of treatment. Exon skipping of AURKA,
CCNA2, and p27 was mostly observed at 30 M.
DDD00107587 Causes Cell Cycle Arrest—We next tested the
effect of DDD00107587 on cell cycle progression in exponen-
tially dividing cells. HeLa cells were treated eitherwith aDMSO
negative control orwith a final concentration of 10, 20, or 30M
DDD00107587 for 4, 8, and 24 h before labelingwith propidium
iodide and analysis by flow cytometry (Fig. 5A). No cell cycle
changes were observed after 4 h of treatment at any concentra-
tion tested. In the presence of 10 M DDD00107587 8 h after
treatment, the proportion of cells in G2, M, and S phases
increased, with a concomitant decrease in the number of G1
phase cells. This effect increased over time, with40% of cells
in G2 and M phase and 50% in S phase 24 h after treatment
withDDD00107587. This contrastedwith 14% inG2 andMand
23% in S phase in theDMSOcontrol (Fig. 5B). Cells treatedwith
higher concentrations showed a delayed cell cycle arrest. 8 h of
treatment with either 20 or 30MDDD00107587 exhibited the
same cell cycle profile as the DMSO control. At 24 h, however,
FIGURE3.Effect ofDDD00107587on in vitro splicing.A, chemical structure
of DDD00107587. B, denaturing gel analysis of 32P-labeled MINX or Ad1 RNA
isolated from splicing reactions incubatedwith dimethyl sulfoxide (DMSO) or
different concentrations of DDD00107587. The positions of the lariat intron,
lariat, pre-mRNA, and fully spliced mRNA are shown top to bottom on the
left. C, formation of splicing complex on the MINX pre-mRNA in the pres-
ence of DMSO or 250 M DDD00107587. The reactions were stopped at
the time points indicated, and the products were analyzed on a native
agarose gel. The positions of the splicing complexes B, A, and H are indi-
cated on the left.
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cells treated with 20 or 30 M DDD00107587 also showed G2,
M, and S phase arrest, with40% of cells in S and30% in G2
and M phase in the presence of 20 M and 30% of cells in S
and 24% in G2 and M phase when treated with 30 M
DDD00107587.
To test whether cells arrested by DDD000107587 showed
any inhibition of DNA synthesis, HeLa cells were pulse-labeled
with EdU either 4, 8, or 24 h after treatment with different
concentrations of DDD000107587 (Fig. 6). DDD00107587
showed a time- and dose-dependent effect on reducing DNA
synthesis, with the greatest reduction in DNA synthesis at 30
M.After 4 h of treatment with 30MDDD00107587, amodest
reduction in DNA synthesis was detected (20%), which
increased over time until after 24 h no incorporation of EdU
could be detected at this concentration. Reduction inDNA syn-
thesis levels in HeLa cells was first observed after 8 h of treat-
ment with 20 M, with essentially complete inhibition after
24 h. At the lowest concentration tested, 10 M, a decrease in
DNA synthesis could only be detected after 24 h.
Next, we tested whether DDD00107587 had a similar inhib-
itory effect on levels of newly transcribed RNA in HeLa cells by
pulse labelingwith EU (see “Experimental Procedures”). In con-
trast with the reduced levels of DNA synthesis, total RNA syn-
thesis levels appeared less affected byDDD00107587 (Fig. 7). In
particular, nucleoplasmic transcription levels showed minimal
reduction, consistent with the RT-PCR data (Fig. 4) showing an
accumulation of unspliced pre-mRNA. Interestingly, the main
inhibitory effect on nuclear RNA caused by DDD00107587 was
a decrease in nucleolar RNA levels, likely representing
decreased rRNA synthesis (Fig. 7).
Loss of Cajal Bodies after Treatment with DDD00107587—
Next, we investigated the effect of DDD00107587 on sub-
nuclear structures and specifically on the organization of
pre-mRNA splicing factors within the nucleus. To analyze the
effect of DDD00107587 on splicing speckles, HeLa cells were
treated for 4 h with either a DMSO negative control or with
10, 20, or 30 M DDD00107587 before cells were fixed and
stained with an antibody to label the splicing factor SC35 (Fig.
8). Interestingly, no enlargement and rounding up of the speck-
les was detected (Fig. 8A), in contrast to what is typically
observed when transcription is inhibited (Fig. 8B). However,
DDD00107587 induced a dose-dependent disruption of CBs.
Thus, antibodies to each of four CB markers (coilin, SMN,
TMGcap, andY12) label bright foci, corresponding toCBs (Fig.
9, arrowheads), in cells treated with the DMSO control. Intact
CBs were still visible when HeLa cells were treated for 4 h with
10 M DDD00107587. However, after 4 h of treatment with
either 20 or 30 M DDD00107587, the bright CB foci were no
longer observed, and coilin instead forms numerous microdots
FIGURE 4. Splicing inhibition in cells treated with DDD00107587. Semi-
quantitativeRT-PCRanalysis of cells treatedwith increasingconcentrationsof
DDD00107587 and DMSO for 4, 8, and 24 h. HeLa cells were investigated for
intron inclusion of RIOK3, HPV18 E6, BRD2, and Hsp40 as well as the exon
skippingofMCL1,AURKA,CCNA2, andp27 (A). HEK293 cellswere examined for
intron inclusion of RIOK3, BRD2, and Hsp40, the alternative splicing the ade-
novirus E1A gene and the exon skipping ofMCL1, AURKA, CCNA2, and p27 (B).
The positions of different cDNAproducts are pictured on the right of each gel
image, and molecular weight markers are shown on the left. Lane M, marker
(hyperladder, 1 kb).
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throughout the nucleoplasm (Fig. 9A). This change in coilin
localization was consistently observed in essentially all cells,
whereas a subset of these cells also showed SMN forming a
multitude of tiny dots in the nucleoplasm (Fig. 9D). Other cells
treated for 4 hwith either 20 or 30MDDD00107587 displayed
instead large SMN aggregates in the cytoplasm (Fig. 9D). The
coilin microfoci mostly did not colocalize with SMN and never
colocalized in cells showing SMN aggregates in the cytoplasm
(Fig. 10A). In contrast with coilin and SMN, Y12 and TMG are
not only located in CBs but also in nuclear speckles. After treat-
ment for 4 h with either 20 or 30 M DDD00107587, both the
Y12 and TMG antibodies no longer stained CBs, although both
still labeled a similar pattern of speckles compared with the
DMSO control. Furthermore, the morphology of the splicing
FIGURE 5. DDD00107587 induces S/G2 and M phase arrest. Cell cycle analysis was performed on HeLa cells treated with DMSO and 10, 20, and 30 M
DDD00107587 for 4, 8, and 24 h. Cellular DNA content wasmeasured by propidium iodide staining followed by flow cytometry analysis. A, histograms of DNA
content. B, cell cycle distributions quantified using the Watson model (51).
FIGURE 6.DDD00107587 reduces DNA synthesis.HeLa cells were treated with DMSO and 10, 20, and 30MDDD00107587 for 4, 8, and 24 h. Areas of active
DNA replication were marked by pulse labeling with EdU 20 min before the cells were fixed. Scale bars, 40 m.
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speckles showed little or no change (Fig. 9, B andC). In the case
of Y12, some cells also showed cytoplasmic aggregates in the
presence of 30MDDD00107587 for 4 h. These Y12 aggregates
colocalize with the cytoplasmic SMN aggregates (Fig. 10B,
arrows).
As it is known that RNA polymerase II activity is required for
CB integrity, we next compared the effect of DDD00107587 on
the redistribution of CB components with that induced by
treating cells with transcription inhibitors. HeLa cells were
treatedwith either 50, 100, or 150MDRB for 4 h to block RNA
polymerase II (Fig. 11). This showed that the CB disruption in
response to DRB treatment is different from that induced by
DDD00107587. Thus, the staining with both the Y12 and anti-
TMG antibodies show that in the presence of either 100 or 150
M DRB for 4 h, the nuclear speckles become more rounded
and increase in size (Fig. 12,C andD). Coilin and SMNwere still
visible in foci after 4 h of incubation with 50 M DRB, but they
no longer colocalized with snRNP antigens Y12 and TMG.
After the total disruption ofCBs caused by 4 h of treatmentwith
either 100 or 150 M DRB, coilin relocated into nucleolar caps
(Fig. 12A), as observed previously (29), whereas SMN could
mainly be detected in a diffuse cytoplasmic pool (Fig. 12B).
DISCUSSION
Using a recently described ELISA-based high throughput
screening in vitro splicing assay (17), we screened a diverse
small molecule library of 71,504 compounds. This primary
screenwas followedwith independent, secondary screens using
a combination of different in vitro splicing assay formats. We
have thereby identified new small molecule splicing inhibitors,
which are active in vitro and in cells. These small molecule
splicing inhibitors are structurally distinct from previously
described natural compound splicing inhibitors. One of these
new splicing inhibitors,DDD00107587 (2-((7methoxy-4-meth-
ylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(3H)-one, was
characterized in more detail with respect to its effect on spli-
ceosome assembly and nuclear structure. For practical reasons
we have renamed DDD00107587 as madrasin (2-((7methoxy-
4-methylquinazolin-2-yl)amino)-5,6-dimethylpyrimidin-4(3H)-one
RNAsplicing inhibitor).
Several different classes of compounds have been reported to
inhibit splicing in vitro and/or to modify alternative splicing
of specific pre-mRNA transcripts in cells. These compounds
include acetylation/deacetylation inhibitors (23), kinase inhib-
itors (23, 30), phosphatase inhibitors (31), topoisomerase I
inhibitors (32), and cardiotonic steroids (16, 33). However, very
few natural compounds and their synthetic derivatives have
been reported to inhibit splicing both in vitro and in vivo e.g.
FR901464 (8), GEX1A (10), pladienolide B, pladienolide D (9),
and isogengketin (12).
Madrasin is not related in structure to these previously
described inhibitors. It prevents formation of both splicing
intermediates and products in vitro and interferes with one or
more early steps in the pathway of spliceosome assembly,
allowing the formation of the A complex but blocking the for-
mation of larger spliceosome complexes. Other previously
described splicing inhibitors have also been shown to target
early events in the spliceosome assembly pathway, resulting
from their having the same target, i.e. SF3b. This is a multipro-
tein subunit of the U2 snRNP that is present in the A complex.
For example, SSA and pladienolide (27) both stall spliceosome
assembly after A complex formation. However, despite having
the same target SF3b, meayamycin has been reported to
stop the splicing process after E complex formation (34). To
date, themolecular target has only been identified for the splic-
ing modulators isolated from the broth of bacteria, e.g.
FR901464, pladienolide, andGX1Aand their derivatives, which
all bind the SF3b subcomplex of U2 snRNP.
FIGURE 7.DDD00107587doesnot inhibit transcriptionof RNApolymerase II.RNA synthesis inHeLa cells treatedwithDMSOor 10, 20, and 30M for either
4 or 24 h was analyzed by EU pulse labeling. Scale bars, 30 m.
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Splicing inhibition has long been associated with cell cycle
arrest. Not only has the down-regulation of splicing factors
such as SFRS1, SFRS2, and U2AF35 (35–37) by siRNA deple-
tion been shown to arrest cells in G2 andM, but treatment with
splicing inhibitors such as SSA (HeLa cells), GEX1A (WI-38
cells), and E7107, as well as pladienolide (WiDr cells), all arrest
cells in G1, G2, and M phase (8, 38–40). The cell cycle arrest
caused by the inhibitors shown to target SF3b has been mainly
attributed to the inhibition of splicing of the p27 pre-mRNA.
p27 is a cyclin-dependent kinase inhibitor important for the
regulation of cell cycle progression. Altered p27 splicing results
in the expression of a C-terminally truncated version of the p27
protein (8). Recently, the effect of SSA on splicing was studied
in more detail using a splicing-sensitive microarray, which
showed that in addition to inhibition of p27 splicing, the splic-
ing of other genes important for cell cycle progression, includ-
ing CCNA2 and AURKA, was also affected (28).
We demonstrate here thatmadrasin shows a dose- and time-
dependent inhibitory effect on cell cycle progression in HeLa
cells. Lowdoses (10M) ofmadrasin show a clear accumulation
of cells in S, G2, and M phases after 8 and 24 h of treatment.
Higher doses of madrasin also result in the accumulation of
cells arrested in S, G2, and M. However, the cell cycle arrest at
20 and 30Mmadrasin could only be detected after 24 h, which
suggests a block in the transition of all cell cycle stages.Our data
indicate that the cell cycle arrest induced by 10 M madrasin
might be different from that observed for the two higher con-
centrations. Like the SF3b targeting compounds, madrasin also
modulates the alternative splicing ofMCL1, CCNA2, AURKA,
and p27. However, exon skipping of these genes was almost
exclusively detected at 20 and 30M and therefore is unlikely to
account for the cell cycle arrest induced by 10 M madrasin.
The cell cycle arrest seen with the higher concentrations coin-
cides with a reduction in DNA synthesis levels as shown by the
reduced incorporation of EdU in cells treatedwith 20 and 30M
madrasin for 8 h. In contrast, a reduction in DNA synthesis, as
judged by reduced EdU incorporation, was only detected after
24 h of treatment, whereas cell cycle arrest was observed after
8 h in the presence of 10 M madrasin. Even though inhibition
of DNA synthesis caused either by DNA damage or by the
depletion of deoxyribonucleotide precursors is a well known
cause of cell cycle arrest, it is likely that the cell cycle arrest
caused bymadrasin results from altered splicing of one ormore
transcripts that encode proteins needed for normal cell cycle
progression. Therefore, the observed inhibition of DNA syn-
thesis is more likely an indirect effect.
It has been previously reported that either treatment of cells
with splicing inhibitors, e.g. SSA, or the down-regulation of
gene expression caused by transcription inhibitors, e.g. DRB,
changes the morphology of splicing speckles, which become
round and enlarged (41). Splicing speckles are granules located
in interchromatin regions, which are enriched in splicing fac-
tors (41). Treatment with madrasin caused little or no reduc-
tion in RNA polymerase II transcription, as judged by nucleo-
plasmic EU incorporation in HeLa cells. In agreement with
these findings, madrasin treatment also did not result in mor-
phological changes of nuclear speckles. However, treatment
with madrasin did result in the disruption of Cajal bodies in
HeLa cells.
In contrast to polymerase II transcription, a noticeable
reduction in newly synthesized rRNAwas observed after 24 h of
incubation with madrasin. A possibility for this decrease in
rRNA synthesis might be indirect effects caused by splicing
inhibition. Besides the down-regulation of factors important
for rRNA transcription, splicing inhibitionmight also cause a
decrease in the production of small nucleolar RNAs. Small
nucleolar RNAs are essential for the maturation of rRNA in
the nucleolus and most small nucleolar RNAs in mammalian
cells are located in introns and processed from spliced
introns (42).
FIGURE 8. Splicing speckles morphology is not changed by treatment
with DDD00107587. SC35 immunofluorescence of HeLa cells treated with
DMSOor 10, 20, and 30MDDD00107587 (B) and 50, 100, and 150MDRB (A)
for 4 h. Scale bars, 15 m.
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CBs play an important role not only in the maturation of
small nucleolar RNAs, small Cajal body-specific RNAs, and
telomeraseRNAsbut also in thematuration of the spliceosomal
snRNPs (43). It is known that the integrity of CBs depends on
ongoing RNA synthesis, and inhibition of transcription leads to
the disruption of CBs (41). As RNA polymerase II transcription
is not prevented by madrasin treatment, another mechanism
must be responsible for causing the loss of CBs. Redistribution
of coilin throughout the nucleus independently of transcription
inhibition has been described after up-regulation of PA28
(29). Another difference between the disruption of CBs caused
by transcription inhibition and by madrasin treatment is the
effect on coilin localization. Coilin relocates to nucleolar caps
after transcription inhibition, but not, as shown here, after
FIGURE 9.Cajal bodydisruptionafter treatmentwithDDD00107587.HeLa cells treatedwithDMSOor 10, 20, and 30M for 4 hwere stainedwith anti-coilin
(A), anti-Y12 (B), anti-TMG (C), and anti-SMN (D) antibodies, respectively. Arrowheads denote intact CBs. Scale bars, 15 m.
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madrasin treatment, when coilin relocates to form numerous
microfoci throughout the nucleoplasm.
During the cell cycle CBs disassemble in M phase and reap-
pear as multiple small foci in early G1 phase. It is unlikely that
the changes seen in the localization of coilin after madrasin
treatment are indirectly due to changes in the cell cycle, how-
ever, as no cell cycle arrest was observed after 4 h treatment
with madrasin by which time CB disruption and changes in
coilin localization were present in all cells. In addition, the
nuclear localization of other CB components analyzed also
behave differently after treatment of cells with madrasin, as
compared with transcription inhibition. For example, after
transcription inhibition, the snRNPs detected with the Y12
antibody are located in enlarged, rounded splicing speckles,
whereas Y12 instead labels cytoplasmic aggregates, as well as
morphologically normal splicing speckles, after a 4 h treatment
of HeLa cells with 30Mmadrasin (Fig. 9). To date, none of the
previously described molecules that alter splicing have been
shown to cause a similar disruption of CBs. Therefore, madra-
sin provides a unique chemical tool with which to study the
relationship between splicing and CBs in greater detail.
Interestingly, madrasin does not inhibit splicing of all tran-
scripts we tested in vivo. For example, pre-mRNA splicing of
the Hsp40 pre-mRNA was relatively unaffected by the same
concentration and time of treatment with madrasin that
strongly altered the splicing of RIOK3. It was previously
assumed that general splicing inhibitors, like SSA, which target
the U2 snRNP splicing factor SF3b 155, would likely cause inhi-
bition of all pre-mRNA splicing, because U2 snRNP is thought
to be needed for splicing of all GT-AG introns. However Cor-
rionero et al. (28) showed recently using splicing arrays to
examine global splicing events that, instead of affecting all tran-
scripts, SSA alters splicing of only a subset of genes, 3 h after
treatment. To analyze the full extent of the splicing changes
induced bymadrasin and compare this with the effects of other
splicing inhibitors, it will be important in the future to assess
also changes in global transcription levels and alternative splic-
ing patterns.
Our results highlight the potential of madrasin as a tool that
can be used to dissect the splicing mechanism in vitro and in
cells. However, as madrasin is not a natural product, rather it
was identified from a library of drug-like small molecules, its
further development may also prove useful in understanding
the therapeutic potential of splicing inhibition. Increasingly,
FIGURE 10. Subcellular localization of SMN, coilin, and Y12 after treat-
ment with DDD00107587. HeLa cells were treated for 4 h with DMSO or 30
M DDD00107587. The localization of SMN and coilin (A) as well as SMN and
Y12 (B) was visualized by immunostaining. Arrowsmark the colocalization of
cytoplasmic SMN and Y12 aggregates in the presence of DDD00107587.
Arrowheads denote intact CBs. Scale bars, 15 m.
FIGURE 11. DRB inhibits transcription of RNA polymerase II. HeLa cells
were incubated for 4 hwith DRB before the cells were incubatedwith EU that
was incorporated into newly synthesized RNA for 20 min. Cells were then
fixed, and labeled RNA was detected with the help of a fluorescent micro-
scope. Scale bar, 40 m.
Identification of New Small Molecule Splicing Inhibitors
DECEMBER 12, 2014•VOLUME 289•NUMBER 50 JOURNAL OF BIOLOGICAL CHEMISTRY 34695
 at U
N
IV
ERSITY
 O
F D
U
N
D
EE on M
ay 20, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
pre-mRNA splicing is becoming an attractive target for drug
discovery (44–47). Splicing inhibitors, including meamyacin
(34), isoginkgetin (48), and pladienolides (49), have been shown
to have anticancer properties. In the case of pladienolides, it has
been demonstrated that the targeting of SF3b is the direct
mechanism of their antitumor activity (40). Most recently,
while this manuscript was under review, Naryshkin et al. (50)
have reported the identification of small molecules that alter
the splicing of transcripts from the SMN2 gene, which is linked
with genetic disease causing neuromuscular degeneration and
mortality. Consistent with the known effects of other splicing
inhibitors, madrasin exhibits cytostatic activity. In addition,
madrasin also alters the splicing of at least two viral oncogenes,
i.e. E1A (adenovirus) and theHPV18E6 (humanpapillomavirus
type 18), which may be interesting with regard to the effects of
madrasin-related compounds on viral reproduction and their
potential to transform cells.
In summary, we have identified a new class of small molecule
splicing modulators that inhibit splicing of multiple introns
both in vitro and in cells. Further characterization of this com-
pound, and its related derivatives, may lead to the development
of more potent and transcript-selective compounds with uses
in studying the splicing mechanism and potential applications
as antiviral and/or anti-cancer agents.
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FIGURE 12. Cajal body disruption after treatment with DRB. HeLa cells were incubated with DMSO or 50, 100, and 150 M DRB for 4 h and stained with
anti-coilin (A), anti-SMN (B), anti-Y12 (C), and anti-TMG (D) antibodies respectively. Arrowheads denote intact CBs. Scale bar, 15 m.
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PAGES 34687 AND 34688:
Two figures contain minor errors. In panel A of Fig. 2, the terms
spliced and unspliced are reversed. The chemical structure shown in
panel A of Fig. 3 should include two additional methyl groups attached
to the ring at the right hand side of themolecule. This structure is shown
correctly in supplemental Table 2 (A9). These corrections do not affect
the interpretation of the results or conclusions of this work.
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